Trends in Venture Deal Term Sheets: Favorable Climate for Founders

If you are raising capital now, the path you are about to embark on can be stressful and littered with obstacles, but the light at the end of the tunnel is worth the trials and tribulations. Despite the inherent challenges of fundraising, the current climate is quite...

Maximizing Your JP Morgan Healthcare Conference

The JP Morgan Healthcare Conference, or “JPM”, is the healthcare conference of the year. Companies from all over the world convene in San Francisco to setup meetings with investors, prospective partners, service providers, etc. and lay the groundwork for much of the...

Maximizing the Likelihood of Closing a Deal This Year

A few months ago, I posted a related article about deal timing titled ‘Maintaining Deal Momentum in the Summer Months’.  Now it is early August, and we are deep in the summer slowdown.  Many of us are enjoying the last stints of our summer holidays before returning to...

What happened to the value of priority review vouchers (PRV)?

The FDA Amendments Act of 2007 created an incentive system for drug developers to pursue tropical neglected diseases, whereby upon approval of a product for a designated tropical disease, the drug developer would receive a voucher that could be applied to receive a...

Immunomedics and venBio: Activist Investors in Biotech

This has certainly been an eventful few months for Immunomedics and its largest shareholder, venBio.  In case you haven’t been following, below is a brief replay: Towards the end of last year, venBio, the beneficial owner of approximately 9.9% of the outstanding...